DELCATH SYSTEMS INC

NASDAQ: DCTH (Delcath Systems, Inc.)

Last update: 18 Aug, 6:47AM

7.50

0.01 (0.13%)

Previous Close 7.49
Open 7.50
Volume 113,374
Avg. Volume (3M) 246,161
Market Cap 209,996,256
Price / Earnings (Forward) 100.00
Price / Sales 16.85
Price / Book 56.84
52 Weeks Range
2.25 (-70%) — 9.18 (22%)
Earnings Date 11 Nov 2024 - 15 Nov 2024
Operating Margin (TTM) -50.37%
Diluted EPS (TTM) -2.52
Quarterly Revenue Growth (YOY) 1,468.90%
Total Debt/Equity (MRQ) 27.91%
Current Ratio (MRQ) 2.56
Operating Cash Flow (TTM) -31.37 M
Levered Free Cash Flow (TTM) -16.64 M
Return on Assets (TTM) -81.99%
Return on Equity (TTM) -478.59%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Bearish
Medical Devices (Global) Mixed Bearish
Stock Delcath Systems, Inc. Mixed Bullish

Stockmoo Score

-1.3
Analyst Consensus NA
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages -1.5
Technical Oscillators -0.5
Average -1.33

Similar Stocks

Stock Market Cap DY P/E P/B
DCTH 210 M - - 56.84
MASI 6 B - 79.41 5.61
LIVN 3 B - - 2.32
TNDM 2 B - - 10.37
NVCR 2 B - - 4.40
ESTA 1 B - - 26.63

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Sector Healthcare
Industry Medical Devices
Investment Style Small Core
% Held by Insiders 2.71%
% Held by Institutions 37.51%

No data within this time range.

No data within this time range.

Date Type Details
17 Oct 2024 Announcement Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
20 Sep 2024 Announcement Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Sep 2024 Announcement Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups
28 Aug 2024 Announcement Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
28 Aug 2024 Announcement Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
27 Aug 2024 Announcement Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients
26 Aug 2024 Announcement Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors
20 Aug 2024 Announcement Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress
12 Aug 2024 Announcement Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Aug 2024 Announcement Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™
05 Aug 2024 Announcement Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
30 Jul 2024 Announcement Delcath Systems to Participate in Upcoming Investor Conferences
22 Jul 2024 Announcement Delcath Systems to Host Second Quarter 2024 Earnings Call
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria